Versor Investments LP Invests $519,000 in Lantheus Holdings, Inc. $LNTH

Versor Investments LP acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 7,800 shares of the medical equipment provider’s stock, valued at approximately $519,000.

A number of other institutional investors have also modified their holdings of LNTH. Quantbot Technologies LP acquired a new stake in Lantheus in the 3rd quarter valued at $1,847,000. American Assets Inc. acquired a new position in shares of Lantheus during the third quarter worth about $872,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Lantheus in the third quarter worth about $2,184,000. Assetmark Inc. grew its stake in shares of Lantheus by 20.1% in the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after buying an additional 19,844 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Lantheus by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock valued at $356,590,000 after buying an additional 115,338 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. Mizuho raised their price target on shares of Lantheus from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, May 8th. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Finally, Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.71.

Lantheus Stock Performance

Shares of LNTH opened at $96.46 on Thursday. The firm has a market cap of $6.28 billion, a price-to-earnings ratio of 23.24 and a beta of -0.08. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The business’s 50 day moving average is $81.24 and its two-hundred day moving average is $69.94. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $98.27.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts forecast that Lantheus Holdings, Inc. will post 4.3 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.